Clinical Journal of Diabetes Care and Control
ISSN: 2642-0872

Academic Strive
Researcher's perception is our reality

Short Communication *Volume 6 Issue 2*

Glycolysis and Enzyme Deficiency Diseases: Understanding Metabolic Disruptions

Akram M[1]*, Rashid A[2], Perez-Jorge D[3], Khan FS[1], Iftikhar M[1], Tutar Y[4], Garcia-Sierra F[5], Al-Malki RS[6], Ozdemir FA[7], Solowski G[7], Fitria N[8], Altable M[9], Sfera A[10], Brogi S[11] and Soonmin H[12]

[1]Department of Eastern Medicine, Government College University, Pakistan

[2]Government College University, Pakistan

[3]DISAE Research Group, University of La Laguna, Spain

[4]Division of Biochemistry, Recep Tayyip Erdogan University, Rize Turkey

[5]Department of Cell Biology, Center of Research and Advanced Studies of the National Polytechnic Institute, Mexico

[6]Department of Pharmacology and Toxicology, Umm Al Qura University, Saudi Arabia

[7]Department of Molecular Biology and Genetics, Bingol University, Turkiye

[8]Department of Pharmacology and Clinical Pharmacy, Universitas Andalas, Indonesia

[9]Department of Neurology, Virgen de Africa Clinic, Spain

[10]Department of Psychiatry, Patton State Hospital, USA

[11]Department of Pharmacy, University of Pisa, Italy

[12]Department of Health and Life Sciences, INTI International University, Malaysia

***Corresponding author:** Muhammad Akram, Associate Professor, Department of Eastern Medicine, Government College University, Faisalabad, Pakistan, Tel: 923452888394; Email: makram_0451@hotmail.com

Received Date: September 18, 2024; **Published Date:** September 30, 2024

Abstract

One essential metabolic process that breaks down glucose to produce ATP is glycolysis. Metabolism is severely disrupted by enzyme deficits in this route, including those that impair pyruvate kinase, phosphofructokinase, or hexokinase. The generation of energy can be hampered by these inadequacies, which can result in symptoms varying from lactic acidosis to exhaustion and cramping in the muscles. Knowing the function of particular glycolytic enzymes and the deficits in them helps with accurate diagnosis and efficient treatment of a variety of metabolic illnesses. In disorders linked to glycolysis, this understanding is essential for creating tailored therapies and enhancing patient outcomes.

Keywords: Glycolysis; Metabolic Disorders; Energy Production; Pyruvate Kinase Deficiency; Lactic Acidosis

Abbreviations

ATP: Adenosine Triphosphate; HGP: Hepatic Glucose Production; PEP: Phosphoenolpyruvate; PFK-1: Phosphofructokinase-1.

Introduction

The energy requirements of muscle cells are substantial, especially during vigorous physical activity like exercise. In order to quickly produce ATP by breaking down glucose into

pyruvate, glycolysis is essential for achieving these energy demands. Glycolysis is increased to supply the ATP required to power muscular contractions at times of high energy demand, such as during intense exercise. Because of this, muscles may continue to contract and perform even during anaerobic activity, when oxygen availability is restricted [1]. Maintaining blood glucose levels and controlling the body's overall energy metabolism are major functions of the liver, a primary metabolic organ. Gluconeogenesis, the process by which glucose is produced in the liver and glycogen storage are two of the many purposes of glycolysis. Glycolysis is accelerated in the liver during fasting or times of high energy demand, resulting in the production of glucose that may be delivered into the circulation to power other tissues including the brain and red blood cells [2].

Because red blood cells depend on an on-going supply of ATP to preserve membrane integrity and carry oxygen throughout the body, glycolysis is therefore crucial to the survival and proper operation of these cells. For red blood cells to maintain cellular homeostasis and provide the best possible oxygen transport to tissues, glycolysis efficiency is essential [3]. Among the body's most metabolically active organs, the brain primarily uses glucose as an energy source. The brain uses glycolysis to produce ATP, which is needed for synaptic transmission, ion transport, and neurotransmitter production. Glycolysis is necessary to supply the high energy needs of the brain under normal physiological settings since neurons have limited glycogen reserves and cannot oxidize fatty acids for energy [4].

The discovery that cancer cells show enhanced glucose absorption and glycolytic flux even in the presence of oxygen (aerobic glycolysis) is known as the Warburg effect, named after the German biologist Otto Warburg. This metabolic profile is characteristic of cancer cells and is assumed to facilitate their fast growth and multiplication. Cancer cells are able to produce the biomass and energy needed for cell division while adjusting to the hypoxic and nutrient-deficient tumour microenvironment by preferentially using glycolysis for the creation of ATP [5]. Targeting glycolysis and metabolic vulnerabilities in cancer cells has emerged as a viable technique for cancer treatment; hence, the Warburg effect has important implications for cancer therapy. Through the manipulation of glycolytic pathways or targeting certain metabolic enzymes implicated in glycolysis, scientists hope to specifically impede cancer cell growth and survival while protecting healthy cells. This strategy often referred to as metabolic targeting or metabolic treatment, may lead to the development of brand-new anticancer medications with increased effectiveness and fewer adverse effects [6].

Gaining knowledge about the physiological relevance of glycolysis in various tissues and its deregulation in cancer might help one better understand how metabolism functions in both health and illness. Researchers can find novel therapeutic targets and approaches for the treatment of metabolic diseases and cancer by clarifying the intricate interactions that exist between glycolytic pathways and cellular function [7]. Deficits in the functions of lactate dehydrogenase, phosphoglycerate mutase, phosphofructokinase, and phosphoglycerate kinase indicate significant genetic abnormalities in glycolysis. A few common clinical aspects unify all of these: demonstrate intolerance, the lack of a lactate spike during the forearm exercise test, hemolytic anemia, myoglobinuria, and increased liver and skeletal muscle glycogen deposition [8].

It is well acknowledged that glucose serves as the primary carbon source for the glycolytic pathway, which is essential for cellular metabolism and proliferation. Neurological disorders such as Parkinson's and Alzheimer's, diabetes, obesity, cancer, and amyotrophic lateral sclerosis are all significantly impacted by glycolysis failure [9]. Diabetes is brought on by impaired glycolysis, which is brought on by impaired cellular signaling. Glycolysis controls insulin secretion, and hepatic glucose production (HGP) has been demonstrated to be a useful strategy for preserving euglycemia. Reduced rates of glycolysis in the liver, pancreatic beta cells, and adipose tissue are indicative of type-1 diabetes insulin insufficiency, whereas increased rates of glycolysis in these tissues are indicative of type-2 diabetes hyperinsulinemia [10].

One prevalent characteristic of diabetes is dysregulation of glycolysis, which plays a role in the pathogenesis of the illness [11]. Consequently, dysregulation of glycolysis occurs, resulting in decreased consumption of glucose and increased gluconeogenic synthesis of glucose by the liver. This raises the risk of hyperglycemia and the onset of diabetes complications, including retinopathy, nephropathy, and neuropathy [12]. A compensatory hyperinsulinemia and dysregulation of glycolysis result from peripheral tissue insulin resistance, which impairs glucose uptake and metabolism. Hyperglycemia is exacerbated in the liver by insulin resistance, which stimulates gluconeogenesis and glycogenolysis. Insulin resistance is a result of dysregulated glucose metabolism and glycolysis, which feeds a vicious cycle of hyperglycemia and dysmetabolism [13]. Systemic acidity is the result of lactate buildup in the blood, which is a metabolic problem known as lactic acidosis. It can happen in a number of clinical contexts, such as shock, tissue hypoxia, sepsis, and mitochondrial failure. An imbalance between the generation and elimination of lactate, usually brought on by decreased tissue oxygenation or mitochondrial malfunction, leads to lactic acidosis [14].

The anaerobic enzyme lactate dehydrogenase converts pyruvate to lactate during glycolysis. Normally,

gluconeogenesis and oxidation enable the liver and other organs to quickly eliminate lactate. Lactate build-up in the blood occurs when there is an excess of lactate generation compared to its clearance, which occurs when there is tissue hypoxia or decreased mitochondrial activity [15]. Serious side effects of lactic acidosis can include organ failure, hemodynamic instability, and even death. The goal of treatment is to restore pH and lactate levels by addressing the underlying cause of tissue hypoxia or mitochondrial malfunction, restoring tissue perfusion and oxygenation, and provide supportive care [16].

Exercise intolerance, hemolytic anemia, muscular weakness, and metabolic acidosis are indications of these disorders, which are characterized by reduced glycolytic flux [17]. Because pyruvate kinase catalyzes the conversion of phosphoenolpyruvate (PEP) to pyruvate during glycolysis, pyruvate kinase deficiency is an autosomal recessive condition identified by a lack of the enzyme. Reduced ATP synthesis and a greater dependence on alternate metabolic routes, such as the pentose phosphate pathway, result from poor glycolytic flux caused by insufficient pyruvate kinase activity [18]. Due to their inability to preserve their structural integrity, red blood cells are prematurely destroyed in the spleen, which causes hemolytic anemia. Another uncommon metabolic condition brought on by mutations in the gene encoding phosphofructokinase-1 (PFK-1), the glycolysis rate-limiting enzyme, is phosphofructokinase deficiency [19].

Conclusion

A variety of metabolic illnesses are brought on by enzyme deficits in glycolysis, which impair glucose metabolism. Mild to severe symptoms may come from these inadequacies, which might hinder the creation of energy. Understanding these disturbances emphasizes the significance of enzyme activity in preserving metabolic balance and aids in the diagnosis and treatment of associated disorders.

References

1. Hargreaves M, Spriet LL (2020) Skeletal muscle energy metabolism during exercise. Nature Metabolism 2(9): 817-828.

2. Dienel GA (2019) Brain glucose metabolism: integration of energetics with function. Physiological Reviews 99(1): 949-1045.

3. Hess JR, D'Alessandro A (2022) Red blood cell metabolism and preservation. Rossi's Principles of Transfusion Medicine pp: 143-157.

4. Faria-Pereira A, Morais VA (2022) Synapses: The brain's energy-demanding sites. International Journal of Molecular Sciences 23(7): 3627.

5. Zhao H, Li Y (2021) Cancer Metabolism and Intervention Therapy. Molecular Biomedicine 2(1): 5.

6. Kozal K, Jozwiak P, Krzeslak A (2021) Contemporary perspectives on the Warburg effect inhibition in cancer therapy. Cancer Control 28: 10732748211041243.

7. DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Science Advances 2(5): e1600200.

8. Rocha H (2024) Inborn glycolytic pathway defects. Glycolysis, Academic Press, pp: 321-332.

9. Vallee A, Lecarpentier Y, Guillevin R, Vallee JN (2018) Aerobic glycolysis in amyotrophic lateral sclerosis and Huntington's disease. Reviews in the Neurosciences 29(5): 547-555.

10. Radziuk J, Pye S (2001) Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis. Diabetes Metab Res Rev 17(4): 250-272.

11. Yan X, Hu Y, Wang B, Wang S, Zhang X (2020) Metabolic dysregulation contributes to the progression of Alzheimer's disease. Frontiers in Neuroscience 14: 530219.

12. Bhat N, Mani A (2023) Dysregulation of lipid and glucose metabolism in nonalcoholic fatty liver disease. Nutrients 15(10): 2323.

13. Jellinger PS (2007) Metabolic consequences of hyperglycemia and insulin resistance. Clinical Cornerstone 8: S30-S42.

14. Gomez H, Mizock BA (2019) Hyperlactatemia and lactic acidosis. Critical Care Nephrology, Elsevier 394-404.

15. Duke T (1999) Dysoxia and lactate. Arc Dis Child 81(4): 343-350.

16. Russell A, Rivers EP, Giri PC, Jaehne AK, Nguyen HB (2020) A physiologic approach to hemodynamic monitoring and optimizing oxygen delivery in shock resuscitation. Journal of Clinical Medicine 9(7): 2052.

17. Jaffe ER, Valentine WN (2019) Human Erythroenzymopathies of the Anaerobic Embden-Meyerhof Glycolytic and Associated Pathways. Genetically Abnormal Red Cells, CRC Press 105-136.

18. Shimizu K, Matsuoka Y (2019) Regulation of glycolytic

flux and overflow metabolism depending on the source of energy generation for energy demand. Biotechnology Advances 37(2): 284-305.

19. Taha M, Lopaschuk GD (2007) Alterations in energy metabolism in cardiomyopathies. Ann Med 39(8): 594-607.